文献速递泌尿男性生殖肿瘤

输精管切除术与前列腺癌风险:欧洲癌症与营养前瞻性调查(EPIC)

Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC).
PubMed 文献 · J Clin Oncol · 2017-03-06

在EPIC前瞻性队列中,84,753名35至79岁男性(15%接受过输精管切除术)随访平均15.4年,4,377人诊断前列腺癌。输精管切除术与前列腺癌总体风险、高分级或晚期肿瘤及前列腺癌死亡均无显著关联,仅低中分级风险略有升高。

要点

  • 输精管切除术与前列腺癌总体风险无关(HR 1.05,95%CI 0.96–1.15)。
  • 肿瘤分级异质性P=0.02:低中分级风险升高(HR 1.14,95%CI 1.01–1.29),高分级无关(HR 0.83,95%CI 0.64–1.07)。
  • 输精管切除术与前列腺癌死亡无关(HR 0.88,95%CI 0.68–1.12)。

核心结论

  • 大型欧洲前瞻性研究显示,与未接受输精管切除术的男性相比,接受输精管切除术的男性总体、高分级或晚期前列腺癌风险及前列腺癌死亡风险均未升高。

研究设计与样本

  • 欧洲癌症与营养前瞻性调查(EPIC)前瞻性队列,纳入84,753名35至79岁男性,招募时提供输精管切除术状态信息(15%接受过输精管切除术),随访前列腺癌发病与死亡,采用多变量校正Cox比例风险模型估计关联。

主要发现

  • 平均随访15.4年,4,377名男性诊断前列腺癌,其中641名接受过输精管切除术。
  • 输精管切除术与前列腺癌风险无关(HR 1.05;95%CI 0.96–1.15),按疾病分期或输精管切除术后年数未见关联异质性证据。
  • 肿瘤分级存在一定异质性(P=0.02),低中分级风险升高(HR 1.14;95%CI 1.01–1.29),高分级前列腺癌风险未升高(HR 0.83;95%CI 0.64–1.07)。
  • 输精管切除术与前列腺癌死亡无关(HR 0.88;95%CI 0.68–1.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Vasectomy is a commonly used form of male sterilization, and some studies have suggested that it may be associated with an increased risk of prostate cancer, including more aggressive forms of the disease. We investigated the prospective association of vasectomy with prostate cancer in a large European cohort, with a focus on high-grade and advanced-stage tumors, and death due to prostate cancer. Patients and Methods A total of 84,753 men from the European Prospective Investigation into Cancer and Nutrition (EPIC), aged 35 to 79 years, provided information on vasectomy status (15% with vasectomy) at recruitment and were followed for incidence of prostate cancer and death. We estimated the association of vasectomy with prostate cancer risk overall, by tumor subtype, and for death due to prostate cancer, using multivariable-adjusted Cox proportional hazards models. Results During an average follow-up of 15.4 years, 4,377 men were diagnosed with prostate cancer, including 641 who had undergone a vasectomy. Vasectomy was not associated with prostate cancer risk (hazard ratio [HR], 1.05; 95% CI, 0.96 to 1.15), and no evidence for heterogeneity in the association was observed by stage of disease or years since vasectomy. There was some evidence of heterogeneity by tumor grade ( P = .02), with an increased risk for low-intermediate grade (HR, 1.14; 95% CI, 1.01 to 1.29) but not high-grade prostate cancer (HR, 0.83; 95% CI, 0.64 to 1.07). Vasectomy was not associated with death due to prostate cancer (HR, 0.88; 95% CI, 0.68 to 1.12). Conclusion These findings from a large European prospective study show no elevated risk for overall, high-grade or advanced-stage prostate cancer, or death due to prostate cancer in men who have undergone a vasectomy compared with men who have not.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Smith K, Byrne, Castaño JM, et al. Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Clin Oncol. 2017. PMID: 28375714. doi:10.1200/JCO.2016.70.0062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。